Allegro Ophthalmics expects to deliver some positive news about its Phase II DEL MAR trial that is evaluating the safety and efficacy of Luminate as an adjunctive therapy with anti-VEGFs in patients with diabetic macular edema (DME). Could the news put the company in a position for an initial public offering?
To listen to the podcast, please visit OIS Podcast: “Allegro’s Poised to Deliver Positive News at ASRS; Could an IPO Be Next? We Ask Vicken Karageozian”
